ArticleRevista do Instituto de Medicina Tropical de Sao Paulo2024
Seroconversion and seroreversion rates of anti-Strongyloides IgG in rural areas of the Amazon: a population-based panel study.
Article in Revista do Instituto de Medicina Tropical de Sao Paulo, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using a panel study design, we aimed to estimate the seroconversion and seroreversion rates of anti-Strongyloides IgG antibodies from surveys carried out 11 months apart in a rural community in the Amazon Basin in Brazil. We used enzyme immunoassays to measure anti-Strongyloides IgG antibodies in 325 baseline plasma samples and 224 others that were collected 11 months later from residents in the agricultural settlement of Granada, Acre State. We observed anti-Strongyloides IgG antibodies in 21.8% of the baseline samples (which showed that 3.4% of participants had larvae in their stool) and in 23.7% of the follow-up samples. The seroconversion rate estimated at 9.7 episodes/100 person-years at risk agrees with ongoing transmission. Specific antibodies were relatively short-lived and nine (25.0%) of 36 seropositive participants at baseline were seronegative when retested 11 months later. Fecal surveys can severely underestimate the prevalence of S. stercoralis infection in rural Amazonians. Serology provides a field-deployable diagnostic tool to find high-prevalence populations, identify associated risk factors, and monitor intervention programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.